Back to top
more

KemPharm, Inc. (KMPH)

(Delayed Data from NSDQ)

$1.37 USD

1.37
193,792

+0.06 (4.58%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.37 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study

by Zacks Equity Research

KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.

Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -72% and 13.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5% and 20.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Lyell Immunopharma (LYEL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 51.61% and 960.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last?

by Zacks Equity Research

Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M

by Zacks Equity Research

KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.

Cronos Group (CRON) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cronos (CRON) delivered earnings and revenue surprises of 0% and 7.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study

by Zacks Equity Research

KemPharm (KMPH) initiates dosing in a phase I study to evaluate the cardiovascular safety profile of its lead pipeline candidate, KP1077's sole active API, serdexmethylphenidate.

Implied Volatility Surging for KemPharm (KMPH) Stock Options

by Zacks Equity Research

Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

Implied Volatility Surging for KemPharm (KMPH) Stock Options

by Zacks Equity Research

Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

Radhika Saraogi headshot

Are Options Traders Betting on a Big Move in KemPharm (KMPH) Stock?

by Radhika Saraogi

Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More

by Zacks Equity Research

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).

KemPharma (KMPH) Moves 42.8% Higher: Will This Strength Last?

by Zacks Equity Research

KemPharma (KMPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

KemPharm (KMPH) Soars on FDA Nod for ADHD Treatment, Azstarys

by Zacks Equity Research

The FDA approves KemPharm's (KMPH) NDA for Azstarys for the treatment of attention deficit hyperactivity disorder in patients aged six years and older. Shares rise.

Do Options Traders Know Something About KemPharm (KMPH) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

Kinjel Shah headshot

4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty

by Kinjel Shah

There is uncertainty about the impact of the coronavirus pandemic on the Zacks Medical-Drugs industry. However, with demand trends expected to improve in the second half of 2020, SAVA, KMPH, NERV, ALDX may prove to be good additions to the portfolio.

KemPharma (KMPH) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

KemPharma (KMPH) delivered earnings and revenue surprises of -1100.00% and -63.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

KemPharma (KMPH) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

KemPharma (KMPH) delivered earnings and revenue surprises of -28.57% and -62.81%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

ArQule (ARQL) in Focus: Stock Moves 6.2% Higher

by Zacks Equity Research

ArQule (ARQL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Implied Volatility Surging for KemPharm (KMPH) Stock Options

by Zacks Equity Research

Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

KemPharm Posts Positive Top-Line Results on KP415 Prodrug

by Zacks Equity Research

KemPharm (KMPH) reports positive top-line results from second of three HAP studies on serdexmethylphenidate/KP415 Prodrug, which is contained in lead candidate KP415 that is being developed for ADHD.

    Options Traders Expect Huge Moves in KemPharm (KMPH) Stock

    by Zacks Equity Research

    Investors in KemPharm (KMPH) need to pay close attention to the stock based on moves in the options market lately.

      KemPharm Stock Down Despite Positive Data on ADHD Candidate

      by Zacks Equity Research

      KemPharm (KMPH) presents positive top-line results on ADHD candidate KP415, which meets both primary and secondary endpoints in a pivotal study.

        KemPharm (KMPH) Shares March Higher, Can It Continue?

        by Zacks Equity Research

        KemPharm, Inc. (KMPH) has been on the move lately as the stock has risen by 45.4% in the past four weeks, and it is currently trading well above its 20-Day SMA

          KemPharm (KMPH) Strengthens its ADHD Prodrug Pipeline

          by Zacks Equity Research

          KemPharm, Inc. (KMPH) announced that it has strengthened its attention deficit hyperactivity disorder (ADHD) produg pipeline portfolio.